 |
| Due to new U.S. Treasury rules, companies like AstraZeneca won't be able to avoid taxes on profits earned at home. |
beforeitsnews.com, 2 October 2014
If you’ve ever wondered how multi-billion dollar pharmaceutical companies play dirty, aside from creating drugs which cause adverse side effects for millions and skirting FDA and regulatory testing with acumen, then look no further than the inversion deal– the re-incorporation of a company abroad to avoid paying taxes where money was made right here in America. Due to new U.S. Treasury rules, companies like AstraZeneca (maker of Nexium as well as other nefarious drugs) and Shire won’t be able to avoid taxes on profits earned at home. They are also experiencing a sharp fall in stock prices due to the new Treasury ruling.
Read more »
If you’ve ever wondered how multi-billion dollar pharmaceutical companies play dirty, aside from creating drugs which cause adverse side effects for millions and skirting FDA and regulatory testing with acumen, then look no further than the inversion deal– the re-incorporation of a company abroad to avoid paying taxes where money was made right here in America. Due to new U.S. Treasury rules, companies like AstraZeneca (maker of Nexium as well as other nefarious drugs) and Shire won’t be able to avoid taxes on profits earned at home. They are also experiencing a sharp fall in stock prices due to the new Treasury ruling.